Saturday 17 October 2026 Export OGI’s income statement to Excel — free account

Organigram Global Inc.

OGI Healthcare Drug Manufacturers Specialty & Generic

Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024. In the quarter to June 2026, revenue grew 49.3%, EPS grew 1,966.7% and free cash flow fell 192.3%, each against the same quarter a year earlier.

0.93 0.00 0.00%

Follow OGI

Alert me

Market cap: $131.4M
P/E: 2.0×
Fwd P/E: 11.4×
Dividend yield: —
F-score: 5/9
Altman Z: 0.22
Beneish M: −1.82
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 28.20%

Capital & Financial Ratios $m

Market Cap 131.36

Revenue 223.47

Net Income 62.74

Free Cash Flow (21.14)

Net Debt 6.72

Current Ratio 2.61

Debt/Equity 0.04

P/E ratio 2.00

Fwd P/E 11.40

P/S ratio 0.56

P/B ratio 0.36

Past 5Y EPS Growth —

This Y EPS Growth 440.86%

Next Y EPS Growth (93.41%)

Next Y revenue growth 32.95%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.70%

10-year low 10-year high

P/B against its own 10 years 0.69%

10-year low 10-year high

EV/Sales against its own 10 years 7.87%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	25	98	60	8
Receivables	22	27	46	64
Inventory	60	61	89	119
Other	8	7	8	11
	116	193	204	202

	2023	2024	2025	Q'26
Payables	15	35	64	72
ST’ Debt	1	—	—	2
Other	1	5	26	3
	17	39	90	77

Compound Annual Growth %

	10y	5y	3y
Sales	45.89%	24.30%	18.80%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	14.34%	(7.99%)	7.45%

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	46	44	76	—	—
’25	31	46	51	58	185
’24	27	28	30	33	117
’23	—	—	—	34	120
’23	—	—	—	—	111
’22	—	—	—	—	115
’21	—	—	—	—	62

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(11)	(5)	(3)	—	—
’25	(3)	(11)	10	(1)	(5)
’24	6	(7)	(3)	7	3
’23	—	—	—	(13)	(29)
’23	—	—	—	—	(26)
’22	—	—	—	—	(28)
’21	—	—	—	—	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(13)	(5)	(3)	—	—
’25	(4)	(16)	3	0	(18)
’24	5	(7)	(3)	5	(1)
’23	—	—	—	(18)	(51)
’23	—	—	—	—	(26)
’22	—	—	—	—	(67)
’21	—	—	—	—	(32)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	0.11	(0.01)	0.56	—	—
’25	(0.14)	0.26	(0.03)	(0.20)	(0.14)
’24	(0.14)	(0.22)	0.02	(0.04)	(0.35)
’23	—	—	—	(0.08)	(2.27)
’23	—	—	—	—	(2.09)
’22	—	—	—	—	(0.15)
’21	—	—	—	—	(1.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	8.00	4.04	5.32	2.80	0.97	1.25	0.85	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	33.76	14.56	25.80	7.48	4.12	2.91	2.24
People
People	Employees	—	—	479	770	552	736	882	935	914	1,139
	Revenue/emp, $m	0.00	0.00	0.02	0.08	0.12	0.08	0.13	0.13	0.13	0.16
Income, $m
Income, $m	Revenue	5	10	10	61	65	62	115	120	117	185
	Gross margin, %	82.08	422.39	422.39	60.28	(65.08)	(35.87)	21.65	23.51	29.73	34.81
	EBT	1	22	22	(4)	(109)	(103)	(11)	(187)	(33)	(28)
	EBT margin, %	13.82	223.48	223.48	(7.31)	(168.94)	(165.11)	(9.86)	(156.16)	(28.43)	(14.87)
	Net income	1	0	17	(7)	(101)	(103)	(11)	(184)	(33)	(18)
	Depreciation	1	1	7	7	13	24	20	19	9	13
Per share, $
Per share, $	Revenue	0.08	0.00	0.32	1.72	1.50	0.98	1.48	1.47	1.23	1.45
	Earnings	0.01	(0.09)	0.53	(0.20)	(2.35)	(1.61)	(0.15)	(2.27)	(0.35)	(0.14)
	Cash flow	(0.03)	(0.07)	(0.33)	(0.75)	(0.78)	(0.35)	(0.37)	(0.35)	0.03	(0.04)
	Capex	0.00	0.00	(1.47)	(2.36)	(1.36)	(0.15)	(0.50)	(0.27)	(0.04)	(0.09)
	Free cash flow	(0.03)	(0.07)	(1.80)	(3.11)	(2.13)	(0.50)	(0.87)	(0.62)	(0.01)	(0.14)
	Book value	0.58	0.00	4.80	7.00	5.16	5.91	5.17	2.48	2.36	1.95
	Shares, m	59	97	30	35	43	64	77	81	95	128
Valuation, ×
Valuation, ×	P/E	169.43	30.04	30.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	9.99	3.37	10.95	2.88	0.86	1.47	1.40
	P/B	4.03	4.03	4.03	2.46	0.98	1.81	0.83	0.51	0.77	1.04
	EV/Sales	0.00	0.00	0.00	10.01	3.84	8.64	2.21	0.65	0.63	1.07
	EV/FCF	(6.28)	(6.28)	(6.28)	(5.60)	(2.69)	(16.73)	(3.79)	(1.55)	(71.19)	(11.34)
Cash, $m
Cash, $m	Operating cash flow	(2)	(7)	(10)	(26)	(34)	(23)	(28)	(29)	3	(5)
	Capex	(3)	(25)	(44)	(83)	(59)	(10)	(38)	(22)	(4)	(12)
	Free cash flow	(2)	(7)	(54)	(110)	(92)	(32)	(67)	(51)	(1)	(18)
Balance, $m
Balance, $m	Working capital	29	150	150	115	105	185	131	99	154	113
	Total debt	6	2	78	37	86	0	0	0	0	—
	Net debt	(19)	(100)	(24)	1	30	(145)	(77)	(25)	(98)	(60)
	Shareholders’ equity	34	145	145	247	223	378	399	201	225	250
Returns, %
Returns, %	ROA	1.13	13.56	6.78	(2.57)	(31.31)	(27.10)	(2.52)	(83.34)	(12.82)	(5.05)
	ROIC	0.00	39.65	14.81	1.04	(26.74)	(19.35)	(6.58)	(69.08)	(12.92)	(3.61)
	ROE	1.30	48.70	22.13	(3.68)	(43.15)	(34.29)	(2.89)	(91.57)	(15.67)	(7.46)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%	Compare
OGI Organigram Global Inc.	$131.4M	2.0×	11.4×	+49.28% (above 0%: growing)	n/m	−192.32% (below 0%: shrinking)	39.16%	5.04%
BGM BGM Group Ltd.	$114.7M	144×	44.9×	−2.59% (below 0%: shrinking)	−85.71% (below 0%: shrinking)	+3.00% (above 0%: growing)	7.12%	0.00%	Compare
PROCF Sofgen Pharma S.A	$114.0M	0.1×	4.0×	+17.28% (above 0%: growing)	n/m	+231.11% (above 0%: growing)	56.09%	36.48%	Compare
CPIX Cumberland Pharmaceuticals Inc.	$113.0M	— (loss-making)	— (loss-making)	−56.28% (below 0%: shrinking)	n/m	−82.78% (below 0%: shrinking)	100.00%	(1,898.20%)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
Median of peers	$126.7M	—	44.9×	−2.59%	—	+6.65%	51.00%	(6.44%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Organigram Global Inc. (OGI) key facts

Strength: Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024.
Organigram Global Inc. (OGI) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OGI traded at $0.93, a market capitalization of $131.4 million.
Return on equity was −7.46% and debt-to-equity 0.04.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.22 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.